The agency has accepted the company's Data Access Plan that will allow for the unblinding of the pre-dose selection data.
The new efficacy endpoints include the rate of sustained clinical resolution of COVID-19 symptoms to indicate the change in the clinical outcome witnessed during the pandemic.